HomeAstraZeneca’s antibody treatment shows promising results - Lilly and Regeneron fail to...

AstraZeneca’s antibody treatment shows promising results – Lilly and Regeneron fail to neutralize omicron

Array

Published on

GlaxoSmithKline’s Sotrovimab and AstraZeneca’s Evusheld, retained some ability but antibody treatments by Lilly and Regeneron were unable to neutralize omicron.

The drugs behind the new pills to treat COVID-19 remain very effective against the omicron variant of the virus in lab tests, according to a new study.

However, lab tests also showed that the available antibody therapies — typically given intravenously in hospitals — are substantially less effective against omicron than against earlier variants of the virus. Some antibodies have entirely lost their ability to neutralize omicron at realistic dosages.

For now, the pills remain in short supply during the current omicron wave, which has broken case records in the U.S. and other countries.

The findings corroborate other studies that show most available antibody treatments are less effective against omicron. Drugmakers could design, test and produce new antibody drugs targeted at the omicron variant to overcome the limitations of current therapies, but this process would take months.

“The bottom line is we have countermeasures to treat omicron. That’s good news,” says Yoshihiro Kawaoka, the University of Wisconsin–Madison lead of the study and virologist at the UW School of Veterinary Medicine and the University of Tokyo. “However, this is all in laboratory studies. Whether this translates into humans, we don’t know yet.”

In lab experiments using non-human primate cells, Kawaoka’s team tested a suite of antibody and antiviral therapies against the original strain of the COVID-19 virus and its prominent variants, including the alpha, delta and omicron strains.

Merck’s pill molnupiravir and the intravenous drug remdesivir were just as effective against the omicron variant as they were against earlier viral strains.

Instead of testing Pfizer’s Paxlovid pill, which is designed to be taken orally, the team tested a related drug by Pfizer that is given intravenously. The two drugs disrupt the same part of the viral machinery. The researchers found that the intravenous form of the drug retained its effectiveness against omicron, and this version is currently in clinical trials.

All four antibody treatments the researchers tested were less effective against omicron than against earlier strains of the virus.

Two treatments, sotrovimab by GlaxoSmithKline and Evusheld by AstraZeneca, retained some ability to neutralize the virus. However, they required anywhere from 3 to 100 times more of the drugs to neutralize omicron compared to earlier versions.

AstraZeneca’s antibodies are not approved for use in the U.S.

Two antibody treatments by Lilly and Regeneron were unable to neutralize omicron at common dosages.

These findings are expected given how the omicron variant differs from earlier strains of SARS-CoV-2, the COVID-19 virus. Omicron has dozens of mutations in the spike protein, which the virus uses to enter and infect cells.

Most antibodies were designed to bind to and neutralize the original spike protein and major changes to the protein can make antibodies less likely to attach to it.

In contrast, antiviral pills target the molecular machinery the virus uses to make copies of itself inside cells. The omicron variant only has a few changes to this machinery, which makes it more likely that drugs will retain their ability to disrupt this replication process.

Image Credit: Getty

You were reading: AstraZeneca’s antibody treatment shows promising results – Lilly and Regeneron fail to neutralize omicron

Latest articles

The Way This New Species Kills Its Host is ‘Absolutely Fascinating’ – ‘It’s Like Something Out Of A James Cameron Movie’

The newly discovered species, named Steinernema adamsi, belongs to the Steinernema family of nematodes....

Plant Eaters Beware: Researchers Reveal Surprise Smell Can Prevent Plants Being Eaten

A new study reveals how it is possible to protect plants from the hungry...

Size of Male Genitals: This is a Rare Case Where a Gene Behind It Has Been Identified

It is thought that sexual selection, which includes female preference and the distinct evolutionary...

Do You Know? Some Early Trees Had Forms Unlike Any You’ve Ever Seen – Rare 3D Fossils Show

“We all have a mental concept of what a tree looks like, depending on...

More like this

The Way This New Species Kills Its Host is ‘Absolutely Fascinating’ – ‘It’s Like Something Out Of A James Cameron Movie’

The newly discovered species, named Steinernema adamsi, belongs to the Steinernema family of nematodes....

Plant Eaters Beware: Researchers Reveal Surprise Smell Can Prevent Plants Being Eaten

A new study reveals how it is possible to protect plants from the hungry...

Size of Male Genitals: This is a Rare Case Where a Gene Behind It Has Been Identified

It is thought that sexual selection, which includes female preference and the distinct evolutionary...